The follow-up study has not been completed, so no results regarding elamipretides effectiveness for improving vision loss secondary to AMD are available. While the trial is still ongoing, there are a few takeaways worth noting
The Lancet (2021) This Phase 2 dose-finding trial randomized adults with overweight or obesity without diabetes to cagrilintide at doses from 0.3 to 4.5 mg weekly, placebo, or liraglutide 3.0 mg daily as an active comparator across 57 sites in 10 countries
Holistic Approach: We believe in a comprehensive approach to health, combining advanced therapies with lifestyle and nutritional guidance to help you achieve lasting results
Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
IL-6, TGF-, IL-1, and IL-21 induce the differentiation of mouse and human CD4(+) T cells into T-helper 17 (Th17) cells (Turner et al., 2010)
